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Background
• Younger age has been associated with unrecognized hypertension (HTN) in both
the general pediatric population and in children on dialysis.
• An increased lifetime risk of cardiovascular disease and the association of HTN
with chronic kidney disease (CKD) progression make optimal treatment of
elevated blood pressure (BP) a key component of CKD management.
• The role of age in the recognition and treatment of HTN in non-dialysis pediatric
CKD remains unknown.

Hypotheses
• Young children with CKD are less likely to be diagnosed with hypertension
despite elevated blood pressure readings compared to older children.
• Young children with hypertension are less likely to undergo pharmacologic
treatment.
• Hypertension is more likely to be poorly controlled in young children.
• The incidence of cardiovascular morbidity will be increased in younger patients
due to increased prevalence of unrecognized and untreated hypertension.

Methods
• Prospective, observational cohort study
• Enrollment criteria:
•

Age 0-16 years of age

•

eGFR 30 - 90 ml/min/1.73m2

• Enrollment 2005- present

Methods
•

Exposure: Age
•
<7 years of age
•
>7 to <13 years of age
•
>13 to <18 years of age

•

Outcomes:
•
Blood pressure status
•
Patient medical history intake form
•
Annual standardized blood pressure measurement
•

Anti-hypertensive medication use
•
Report of using ACEi/ARB, CCB, thiazide diuretic

Demographics
Overall,
n=901

0 to <7 years,
n=263

≥7 to <13 years,
n=317

≥13 to ≤18 years,
n=321

Male sex

64% (573)

70% (184)

62% (195)

60% (194)

BMI percentile

69 [39, 91]

65 [37, 85]

69 [41, 91]

72 [42, 93]

Obese (BMI >95th percentile)

18% (162)

14% (37)

18% (58)

21% (67)

Low birth weight (<2500g)

18% (155)

22% (54)

18% (53)

16% (48)

Premature birth (<36 weeks)

12% (108)

29% (49)

10% (29)

10% (30)

Characteristic a

a

Missing data includes low birth weight, n=61; premature, n=33.
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Missing data includes: iGFR, n=110; CKD onset date, n=8. iGFR=iohexol glomerular filtration rate. eGFR= estimated glomerular
filtration rate
a
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Results
Blood pressure status of CKiD study participants by age.
Characteristic
Systolic BP Status
≥90th to <95th percentile
≥95th percentile
Diastolic BP status
≥90th to <95th percentile
≥95th percentile
BP status
Stage 1 HTN
Stage 2 HTN
HTN (stages 1 and 2)
Use of anti-HTN medication

0 to <7 years,
n=507

≥7 to <13 years,
n=1333

≥13 to ≤18 years,
n=1643

10% (49)
19% (95)

8% (105)
16% (208)

5% (89)
8% (126)

13% (65)
23% (119)

7% (99)
13% (171)

6% (93)
11% (173)

28% (140)
4% (21)
32% (161)
43% (220)

18% (241)
3% (46)
22% (287)
65% (863)

12% (197)
4% (65)
16% (262)
72% (1178)
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Results
Blood pressure status of study participants with hypertension stages 1 and 2 by age.
Characteristic
Self-reported hypertension

0 to <7 years,
n=161

≥7 to <13 years,
n=287

≥13 to ≤18 years,
n=262

39% (63)

55% (158)

63% (166)

Current use of anti-HTN medication

90% (57/63)

93% (147/158)

90% (148/165)

No current use of anti-HTN medication

10% (6/63)

7% (11/158)

10% (18/165)

61% (98)

45% (129)

37% (96)

Current use of anti-HTN medication

24% (24/98)

36% (47/129)

43% (41/96)

No current use of anti-HTN medication

76% (74/98)

64% (82/129)

57% (55/96)

No self-reported hypertension
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Results

Blood pressure status
of study participants
with HTN stages 1
and 2 by age.

Results
Unadjusted and adjusted odds ratios (95% CI) of unrecognized
HTN in study participants with hypertension stages 1 and 2.

2.62
2.17

1.41

1.30

Results
Unadjusted and adjusted odds ratios (95% CI) of treatment
use in study participants with unrecognized HTN.

0.78

0.71
0.53
0.41

Limitations
• “Diagnosis” of hypertension based on caregiver report
• Some antihypertensives used for other modalities, but not clarified on intake
• Compliance with medication not assessed

Conclusions
• Incidence of hypertensive BP readings was highest in young children.
• Antihypertensive medication use was less common in young children.
• Children with CKD younger than age 7 years are more likely to have both
underdiagnosed and untreated HTN.
• Given the impact of hypertension on CKD progression and cardiovascular
disease, efforts to improve BP control in young children with CKD are needed.
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